Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: The effect of a nucleoside backbone

Laura Waters*, Loveleen Bansi, David Asboe, Anton Pozniak, Erasmus Smit, Chloe Orkin, Esther Fearnhill, David Dunn, Andrew Phillips

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Abstract

Background: Virological failures on combined antiretroviral therapy still occur. Boosted protease inhibitor (PI/r)-based therapy is a commonly used option after non-nucleoside reverse transcriptase inhibitor (NNRTI) failure, but whether two fully active nucleoside reverse transcriptase inhibitors (NRTIs) are required is unknown. We investigated the effect of an NRTI backbone in individuals receiving PI/r after failing NNRTI-based combined antiretroviral therapy. Methods: A longitudinal analysis of the UK Collaborative HIV Cohort (CHIC) and UK HIV Drug Resistance Database to identify individuals who failed irst-line NNRTI and two NRTIs, and switched to PI/r-based therapy between January 1999 and December 2008 was conducted. We investigated the effect of NRTI on suppression. Results: In total, 470 individuals met study criteria: 19.6%, 34.5% and 46.0% started 0, 1 or =2 NRTIs, respectively. Median CD4+ T-cell count was 223 cells/mm3 and HIV-RNA was 4.3 log10 copies/ml; 246 (52.3%) underwent genotyping before switch. Virological failure occurred in 10.9% and 13% after 48 and 96 weeks, respectively. In multivariable analysis, heterosexual risk group and HIV RNA were independently associated with virological failure; higher CD4+ T-cell count was protective (HR=0.92). Number of new NRTIs or genotypic sensitivity score of backbone had no effect on treatment success rates when modelled as categorical or continuous variables. Conclusions: Successful treatment with a second-line PI/r may not require two active NRTIs. If replicated in clinical trials, these indings could guide future recommendations.

Original languageEnglish
Pages (from-to)213-219
Number of pages7
JournalAntiviral Therapy
Volume18
Issue number2
DOIs
Publication statusPublished - 2013

Fingerprint

Dive into the research topics of 'Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: The effect of a nucleoside backbone'. Together they form a unique fingerprint.

Cite this